Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A systematic review and meta-analysis.
Nanthida Phattraprayoon, Nut Koonrungsesomboon, Mingkwan Na Takuathung
✦ AI-curated · Sources linked
In 30 seconds
This systematic review and meta-analysis evaluated the efficacy of nebulized salbutamol in improving clinical outcomes for infants with transient tachypnea of the newborn (TTN). Analyzing 17 randomized controlled trials involving 1,317 infants, the study found that salbutamol significantly reduced the duration of respiratory support by 14.85 hours and the duration of oxygen requirement by 24.57 hours, although evidence certainty was low to very low.
Key findings
- Salbutamol reduced the duration of respiratory support by 14.85 hours (95% CI [-25.05, -4.65]; p = 0.004).
- The duration of continuous positive airway pressure was decreased by 18.19 hours (95% CI [-30.03, -6.35]; p = 0.003).
- Oxygen requirement duration decreased by 24.57 hours (95% CI [-35.03, -14.10]; p < 0.001).
- No significant effect on duration of tachypnea was observed (MD: -9.93 hours; p = 0.21).
Why it matters
Understanding the efficacy of nebulized salbutamol in TTN can guide clinicians in managing respiratory support for affected infants, potentially improving patient outcomes and resource utilization in neonatal care.
What to keep in mind
The certainty of evidence for all outcomes was low to very low, limiting confidence in the findings.